Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 4.2016. Journal of the National Comprehensive Cancer Network Ettinger, D. S., Wood, D. E., Akerley, W., Bazhenova, L. A., Borghaei, H., Camidge, D. R., Cheney, R. T., Chirieac, L. R., D'Amico, T. A., Dilling, T. J., Dobelbower, M. C., Govindan, R., Hennon, M., Horn, L., Jahan, T. M., Komaki, R., Lackner, R. P., Lanuti, M., Lilenbaum, R., Lin, J., Loo, B. W., Martins, R., Otterson, G. A., Patel, J. D., Pisters, K. M., Reckamp, K., Riely, G. J., Schild, S. E., Shapiro, T. A., Sharma, N., Stevenson, J., Swanson, S. J., Tauer, K., Yang, S. C., Gregory, K., Hughes, M. 2016; 14 (3): 255-264

Abstract

These NCCN Guidelines Insights focus on recent updates in the 2016 NCCN Guidelines for Non-Small Cell Lung Cancer (NSCLC; Versions 1-4). These NCCN Guidelines Insights will discuss new immunotherapeutic agents, such as nivolumab and pembrolizumab, for patients with metastatic NSCLC. For the 2016 update, the NCCN panel recommends immune checkpoint inhibitors as preferred agents (in the absence of contraindications) for second-line and beyond (subsequent) therapy in patients with metastatic NSCLC (both squamous and nonsquamous histologies). Nivolumab and pembrolizumab are preferred based on improved overall survival rates, higher response rates, longer duration of response, and fewer adverse events when compared with docetaxel therapy.

View details for PubMedID 26957612